Oblique Therapeutics announced that its rights issue, which closed June 30, 2026, was fully subscribed. The transaction is expected to raise approximately SEK 14.1 million before (and subject to) fees and related adjustments, strengthening near-term liquidity. The outcome reduces financing uncertainty, though the magnitude is modest versus broader market moves.
Oblique Therapeutics announced that its rights issue, which closed June 30, 2026, was fully subscribed. The transaction is expected to raise approximately SEK 14.1 million before (and subject to) fees and related adjustments, strengthening near-term liquidity. The outcome reduces financing uncertainty, though the magnitude is modest versus broader market moves.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
